Tiger Brokers

GSK Expects 2025 Turnover Growth Of 3%-5%, Core EPS Rise Of 6%-8%, And Core Operating Profit Growth Of 6%-8%

Benzinga
05 Feb

2025 Guidance 

GSK provides its full-year guidance at constant exchange rates (CER). 

  • Turnover is expected to increase between 3 to 5 per cent 
  • Core operating profit is expected to increase between 6 to 8 per cent 
  • Core earnings per share is expected to increase between 6 to 8 per cent 

This guidance is supported by the following turnover expectations for full-year 2025 at CER 

  • Specialty Medicines – expected increase of a low double-digit per cent in turnover 
  • Vaccines – expected decrease of a low single-digit per cent in turnover 
  • General Medicines – expected to be broadly stable for turnover

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10